673 Preliminary Results from a Phase I Dose Escalation Study of ALG.APV-527, a 5T4 X 4–1BB Bispecific Antibody, in Patients with Advanced Solid Tumors Demonstrate Favorable Safety and Biological Activity
Regular and Young Investigator Award Abstracts(2024)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要